The -174GC Interleukin-6 Gene Promoter Polymorphism as a Genetic Marker of Differences in Therapeutic Response to Methotrexate and Leflunomide in Rheumatoid Arthritis
Joint Authors
Martín-Márquez, Beatriz Teresita
Cardona-Muñoz, Ernesto German
Ponce-Guarneros, Manuel
Zavaleta-Muñiz, Soraya Amali
Rodriguez-Jimenez, Norma Alejandra
Vasquez-Jimenez, Jose Clemente
Flores-Chavez, Alejandra
Ruiz-Padilla, A. J.
Saldaña-Cruz, A. M.
Murillo-Vazquez, J. D.
Vazquez-Villegas, M. L.
Sandoval-Garcia, F.
Totsuka-Sutto, S. E.
Gonzalez-Lopez, Laura
Gamez-Nava, Jorge Ivan
Source
Issue
Vol. 2016, Issue 2016 (31 Dec. 2016), pp.1-10, 10 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2016-09-21
Country of Publication
Egypt
No. of Pages
10
Main Subjects
Abstract EN
Objective.
To evaluate the association of -174G/C IL-6 polymorphism with failure in therapeutic response to methotrexate (MTX) or leflunomide (LEF).
This prospective, observational cohort included 96 Mexican-Mestizo patients with moderate or severe rheumatoid arthritis (RA), initiating MTX or LEF, genotyped for IL-6 -174G/C polymorphism by PCR-RFLP.
Therapeutic response was strictly defined: only if patients achieved remission or low disease activity (DAS-28 < 3.2).
Results.
Patients with MTX or LEF had significant decrement in DAS-28 ( p < 0.001 ); nevertheless, only 14% and 12.5% achieved DAS-28 < 3.2 at 3 and 6 months.
After 6 months with any of these drugs the -174G/G genotype carriers (56%) had higher risk of therapeutic failure compared with GC (RR: 1.19, 95% CI: 1.07–1.56).
By analyzing each drug separately, after 6 months with LEF, GG genotype confers higher risk of therapeutic failure than GC (RR = 1.56; 95% CI = 1.05–2.3; p = 0.003 ), or CC (RR = 1.83; 95% CI = 1.07–3.14; p = 0.001 ).
This risk was also observed in the dominant model (RR = 1.33; 95% CI = 1.03–1.72; p = 0.02 ).
Instead, in patients receiving MTX no genotype was predictor of therapeutic failure.
We concluded that IL-6 -174G/G genotype confers higher risk of failure in therapeutic response to LEF in Mexicans and if confirmed in other populations this can be used as promissory genetic marker to differentiate risk of therapeutic failure to LEF.
American Psychological Association (APA)
Ruiz-Padilla, A. J.& Gamez-Nava, Jorge Ivan& Saldaña-Cruz, A. M.& Murillo-Vazquez, J. D.& Vazquez-Villegas, M. L.& Zavaleta-Muñiz, Soraya Amali…[et al.]. 2016. The -174GC Interleukin-6 Gene Promoter Polymorphism as a Genetic Marker of Differences in Therapeutic Response to Methotrexate and Leflunomide in Rheumatoid Arthritis. BioMed Research International،Vol. 2016, no. 2016, pp.1-10.
https://search.emarefa.net/detail/BIM-1097691
Modern Language Association (MLA)
Ruiz-Padilla, A. J.…[et al.]. The -174GC Interleukin-6 Gene Promoter Polymorphism as a Genetic Marker of Differences in Therapeutic Response to Methotrexate and Leflunomide in Rheumatoid Arthritis. BioMed Research International No. 2016 (2016), pp.1-10.
https://search.emarefa.net/detail/BIM-1097691
American Medical Association (AMA)
Ruiz-Padilla, A. J.& Gamez-Nava, Jorge Ivan& Saldaña-Cruz, A. M.& Murillo-Vazquez, J. D.& Vazquez-Villegas, M. L.& Zavaleta-Muñiz, Soraya Amali…[et al.]. The -174GC Interleukin-6 Gene Promoter Polymorphism as a Genetic Marker of Differences in Therapeutic Response to Methotrexate and Leflunomide in Rheumatoid Arthritis. BioMed Research International. 2016. Vol. 2016, no. 2016, pp.1-10.
https://search.emarefa.net/detail/BIM-1097691
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1097691